Quarterly ResultAug 6, 2026, 08:04 AM
InflaRx Q2 2026 Loss €16.2M; Cash €158.4M; Izicopan Progress
AI Summary
InflaRx N.V. reported a net loss of €16.2 million for the six months ended June 30, 2026, an improvement from €22.7 million in the prior year period. The company significantly strengthened its financial position, with cash, cash equivalents, and marketable securities reaching €158.4 million, largely due to €119.3 million in net proceeds from an underwritten public offering in May 2026. This funding is expected to support ongoing operations and clinical development through 2029. InflaRx also highlighted progress in its izicopan program, advancing its development for ANCA-associated vasculitis (AAV) and other renal diseases, with a PK bridging study in China anticipated to start late this year.
Key Highlights
- Net loss for six months ended June 30, 2026 was €16.2 million, compared to €22.7 million in 2025.
- Cash, cash equivalents, and marketable securities totaled €158.4 million as of June 30, 2026.
- Net proceeds from May 2026 underwritten public offering were €119.3 million ($140.4 million).
- Research and development expenses decreased to €8.9 million for six months ended June 30, 2026.
- Operating result for six months ended June 30, 2026 was a loss of €14.3 million.
- Izicopan development advanced for ANCA-associated vasculitis (AAV) and renal diseases.
- Cash runway expected to fund operations and clinical development through 2029.
- Izicopan PK bridging study in China expected to start late 2026.
Price Impact
More from IFRX